Verve Therapeutics, Inc.
VERV
$5.76
-$0.02-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.68% | -2.19% | -0.22% | -9.84% | -27.12% |
| Total Depreciation and Amortization | 23.79% | 35.10% | 53.19% | 74.42% | 94.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.49% | 50.27% | 13.96% | 20.58% | 14.62% |
| Change in Net Operating Assets | -112.77% | -107.05% | 1,276.18% | 33.86% | 111.25% |
| Cash from Operations | -5.45% | -11.12% | 18.47% | -4.07% | -22.25% |
| Capital Expenditure | 59.75% | 62.42% | 65.85% | 53.71% | 29.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 112.62% | 134.24% | 82.97% | 87.70% | 125.91% |
| Cash from Investing | 170.41% | 127.66% | 81.64% | 85.38% | 117.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -76.88% | 169.29% | -29.59% | -29.46% | -35.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 85.59% | -157.30% | 41.51% | 47.64% | 41.51% |
| Cash from Financing | -76.86% | 169.32% | -29.56% | -29.42% | -35.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.06% | 140.43% | 2,290.12% | 846.93% | 79.04% |